Alta Partners led this financing round; it was joined by new investors AM Pappas, Bluewater Capital, GIMV Investment Corp. and Singapore BioInnovations; current investors Ampersand Ventures and CMEA Ventures also participated; SG Cowen Securities Corp. acted as the placement agent
Aclara BioSciences Inc.
Hayward, Calif.
3/23
3
Burrill Agbio Capital Fund invested $3M in a private placement, raising total to $18M; SG Cowen Securities Corp. acted as placement agent
Adolor Corp.
Malvern, Pa.
3/17
8.5
Private placement for $8.5M was led by Tredegar Investments, which joined existing investors S.R. One Ltd., TL Ventures, Alta Partners, OneLiberty Partners, ARCH Venture Partners, Falcon Technologies and Weiss, Peck & Greer Venture Partners
Ambryx Inc. (1st round)
San Diego
10/25
12.3
Ambryx completed a private placement of Series A preferred stock; placement agent was BayCity Capital; other participants included Domain Associates, Prospect Venture Partners, Kingsbury Capital, Rho Management Co., and a group of individual investors including the company's founders, Dr. Lubert Stryer and Paul A. Grayson
Antigenics LLC (4th round)
New York
1/11
28
Lead investors in this round included Deutsche Bank AG, Elan Corp., Sigma-Tau, Zeneca Group plc, Oracle Strategic Partners and SAC Capital
Arcaris Inc. (formerly Ventana Genetics Inc.) (2nd round)
Salt Lake City
5/10
8
Ventana raised $8M in private financing led by Warburg, Pincus Ventures LP
Arena Pharmaceuticals Inc.
San Diego
2/22
17
Arena raised $17M through the sale of its Series D preferred stock in this oversubscribed offering; co-lead investors were MPM Asset Management LLC and International Biomedicine Management Partners Inc.; also participating were Tripos Inc., OrbiMed Advisors LLC and AM Pappas & Associates; ING Barings Furman Selz LLC acted as the placement agent
Argonex Inc. (Series B)
Charlottesville, Va.
12/7
9.6
Argonex raised $9.6M in a second-round private financing; participants included lead investor Advent Capital, of London, as well as Healthcare Ventures LLC and Riggs Capital Partners
Array Biopharma Inc. (Series B)
Boulder, Colo.
12/7
8
Array completed its second round of private equity financing; investors included Boulder Ventures Ltd., Frazier & Co., Arch Venture Partners, Falcon Technology Partners, Advent International and Mitsui & Co. (USA) Inc.
AtheroGenics Inc.
Alpharetta, Ga.
5/17
15.9
Cordova Ventures led the preferred stock financing; participants included current investors Alliance Technology Ventures, Domain Associates, New York Life Insurance Ventures, Sanderling Venture Capital and Sprout Group; new investors included Boston University's Community Technology Fund, Community Investment Partners, Live Oak Equity Partners, Oakwood Medical Investors, Pacific Horizon Ventures and Senmed Medical Ventures
AtheroGenics Inc. (3rd Round)
Alpharetta, Ga.
9/15
8
AtheroGenics closed an $8M tranche from William Blair Capital Parners LLC, completing a $24M Series C convertible preferred stock financing
Atugen Biotechnology GmbH (start-up funding)
Berlin
1/29
13
Atugen completed its initial financing of $20M; MPM Asset Management provided $7M in 6/98; other sources include the German Federal Ministry for Education, Science, Research and Technology ($3.5M), the Technologie-BeteiligungsGesellschaft GmbH ($3M), Ribozyme Pharmaceuticals Inc. ($2M), the Berlin Senate Administration for Commerce and Business ($1.9M) and the Investitions Bank Berlin ($2.7M)
BioImage A/S (1st round)
Copenhagen, Denmark
4/28
17
BioImage completed a $17M private placement, led by funds advised by Apax Partners; BioImage is a spin-off of Novo Nordisk A/S and Novo retains a minority equity stake
BioMarin Pharmaceutical Inc. (2nd round)
Novato, Calif.
4/14
26
BioMarin closed $26M private placement, managed by LaMont Asset Management; participants included A and A Actienbank GmbH, SMS Securities (Sigg-Merkli-Schrodel AG), several other European investors, and Glyko Biomedical Ltd., a founder of BioMarin and the company's lead investor
Biostar Inc. (mezzanine)
Saskatoon, Saskatchewan
2/18
2.1
Biostar closed the 3rd tranche of a US$9.9M financing announced 1/98; investors in this round included the Business Development Bank of Canada, Canadian Medical Discoveries Fund, CIC Industrial Interests Inc., MDS Health Ventures, Royal Bank Capital Corp., Saskatchewan Government Growth Funds III and IV and Working Ventures Canadian Fund Inc. (prices converted at a rate of C$1.50/US$1)
BioStratum Inc. (1st round)
Research Triangle Park, N.C.
4/1
6
BioImage completed $6M private placement with HealthCap (managed by Odlander and Fredrikson & Co. AB) and BankInvest
Biosyn Inc. (1st round)
Philadelphia
7/1
8.5
Private financing comprised of $7M in equity financing, plus $1.5M of debt converted into common stock; financing was led by Warburg, Pincus Equity Partners LP, a private equity investment fund managed by E.M. Warburg, Pincus & Co. LLC
Calydon Inc. (mezzanine)
Sunnyvale, Calif.
6/10
10.1
Barr Rosenberg of AXA Rosenberg Group was the lead investor in this private round, which also included current investor Sequoia Capital and other private investors
Cambridge Genetics Ltd. (1st round)
Cambridge, England
N/A
4 (US$6.4)
Cambridge raised #4M from 3i Group plc, Alta Berkeley Associates, and MVM, the venture fund set up by the government funded Medical Research Council
Ceptyr Inc. (3rd round)
Bothell, Wash.
8/2
11.5
Ceptyr received an $11.5M equity investment from ARCH Venture Partners, Cascade Investment LLC, Falcon Technology Partners, GeneChem Technologies Venture Fund LP, Lombard Odier & Cie and Tredegar Investments Inc.
Circe Biomedical Inc. (1st round)
Lexington, Mass.
4/6
16.4
Formerly operated as wholly owned subsidiary of W.R. Grace & Co., Circe became an independent, private company through a management-led buyout and a $16.4M venture capital financing commitment; investors included Polaris Venture Partners, Bessemer Venture Partners, Advanced Technology Ventures, Spray Venture Partners, BancBoston Ventures Inc. and Mayo Medical Ventures
Coelacanth Corp. (3rd round)
East Windsor, N.J.
5/5
9
Coelacanth raised $9M in Series C financing led by BB Bioventures, managed by MPM Asset Management, and International Biomedicine Holdings; Oak Investment Partners and Oxford Biosciences also participated in the round
Combimatrix Corp.
Burlingame, Calif.
8/10
4
ND
Conjuchem Inc. (2nd Round)
Montreal
8/9
C$12.7 (US$8.5)
Conjuchem raised C$12.7 (US$8.5) in a private financing; leading the financing was new investor Finedix BV, an affiliate of Paris-based Halisol; existing investors included BioCapital Investment, Societe Innovatech du Grand Montreal FSTQ, Business Development Bank of Canada and European Medical Ventures; two-thirds of the funds were disbursed at closing, with the remainder to be disbursed upon the achievement of specified milestones
CpG ImmunoPharmaceuticals (2nd round)
Wellesley, Mass.
8/3
12.9
CpG raised $12.9M in a second-round venture financing to fund clinical studies; participants included lead investor TVM Techno Venture Management, of Munich, Germany, as well as Alafi Capital Co., Quiagen NV, Alpinvest Holding NV, Kredietbank SA Luxembourgeosie and Mulligan Beteiligungs GmbH
Cyclacel Ltd. (2nd round)
Dundee, UK
5/10
5.3 (US$8.5)
Cyclacel raised #5.3M ($US 8.5M) in private financing; new investors included Dresdner Kleinwort Benson Ltd., The Equitable Life Assurance Society, Merifin Capital NV, Northern Venture Trust plc, and Scottish Equity Partnership; previous investors who participated in the new round included the Merlin Fund and Cancer Research Technology Campaign Ltd.; in addition, the University of Dundee and the University of Glasgow were granted 30-day options to increase their shareholdings, which could boost amount raised to #5.5M
Cyclacel Ltd. (3rd round)
Dundee, Scotland
8/16
4 (US$6.5)
Cyclacel completed a private financing in which two private investors, Brian Souter and and Ann Gloag, agreed to invest #2M each
Cytochroma Inc. (1st round)
Kingston, Ontario
N/D
C$2.1 (US$1.4)
Cytochroma received $1.4M in equity financing from the Canadian Medical Discoveries Fund, Working Ventures Canadian Fund and GeneChem
Cytokinetics Inc. (2nd round)
South San Francisco
9/9
20
Cytokinetics completed a Series B preferred stock financing; leading the financing were new investors International Biomedicine Holdings and Paul Allen's Vulcan Ventures; other new investors were Duke University and New Medical Technologies; existing investors were Mayfield Fund and Sevin Rosen Funds; individual investors included William J. Rutter, founder of Chiron Corp.
Dendreon Corp. (Round ND)
Seattle
10/22
10
Dendreon completed a placement of preferred stock led by Vulcan Ventures Inc.; other investors included HealthCare Investment Corp., New York Life Insurance Co., Sanderling Ventures and Kummel Investments LLC
Durect Corp. (2nd round)
Cupertino, Calif.
8/2
20
Durect closed a $20M private placement of preferred convertible stock, led by Brookside Capital, a Bain Capital Fund; additional investors included J.P. Morgan Investment Management, Collinson Howe & Lennox, and Sofinov, a subsidiary of the Caisse de depot et placement du Quebec
Elitra Pharmaceuticals Inc. (2nd round)
San Diego
7/20
16
Private placement was led by Interwest Partners and Walden Group, who were joined by existing investors, Enterprise Partners and Mayfield Fund
Encelle Inc. (mezzanine)
Raleigh, N.C.
4/26
5
Encelle completed $5M Series B financing; investors to date include Intersouth Partners, N.C. Bioscience Investment Fund and N.C. Enterprise Fund, and Cordova Ventures
eNOS Pharmaceuticals Inc. (1st round)
Cambridge, Mass.
8/25
ND
eNOS completed its first round of financing; investors included Polaris Venture Partners and Essex Woodlands Health Ventures Fund IV
EntoMed (1st round)
Strasbourg, France
3/22
3.6
Atlas Venture, CDC Innovation and Oxford Bioscience Partners, along with Rhone-Poulenc Sante Vegetale et Animale, invested in this private offering, which raised FFr2.1M ($3.6M)
Eos Biotechnology Inc. (Round ND)
South San Francisco
9/27
27
Eos completed a private placement of preferred stock; further details ND
Epic Therapeutics Inc. (Funding round ND)
Norwood, Mass.
5/10
12.5
Epic raised $12.5M in private placement coled by MPM Asset Management and ProQuest Investments; other investors included Bessemer Venture Partners and BancBoston Capittal (5/10)
Epicyte Pharmaceutical Inc. (2nd round)
San Diego
1/25
4.5
The company raised $4.5M from TD Javelin Capital Fund II LP, CMEA Life Sciences LP, Viridian Capital LP and Dow Chemical Co.
Epigenomics GmbH (Seed financing)
Berlin
N/A
DM14.5 (US$7.7)
The lead investor in the seed-capital financing was Deutsche Venture Capital Gesellschaft
FibroGen Europe Ltd. (a subsidiary of FibroGen Inc.; 1st and 2nd rounds)
Oulu, Finland
8/2
15.3
Fibrogen raised $15.3M in a private offering sold in two tranches to European investors and 23 institutional investors; BioFund, of Helsinki, Finland, was the lead investor for the first round; BankInvest, of Copenhagen, Denmark, was the lead investor for the second round, with D. Carnegie AB, of Stockholm, Sweden, acting as private placement agent
Gemini Holdings plc (3rd round)
Cambridge, England
N/A
9.2 (US$14.9)
Gemini exceeded its #8M goal, raising #9.2M in a placement with nondisclosed investors
Genmab (Seed funding)
Denmark
3/3
5.5
Medarex Inc. and BankInvest Biomedical Development Venture Fund formed new company to develop and commercialize a portfolio of fully human antibodies derived from Medarex's HuMab Mouse technology; BankInvest is lead investor; co-investors include A/S Dansk Erhvervsinvestering
Genomica Corp. (2nd round)
Boulder, Colo.
3/1
13.6
Punk, Ziegel & Co. managed the private placement of Series B convertible preferred stock; participating new investors included The Kauffmann Fund and Anders L.P.; previous investors who participated in this Series B financing included Falcon Technology Partners, INVESCO Global Health Sciences Fund, ARCH Venture Partners, Boulder Ventures and others
IBC Pharmaceuticals LLC (joint venture of Immunomedics Inc. and Beckman Coulter Inc.)
Morris Plains, N.J.
3/12
2.45
Investors consisted of undisclosed individuals and institutions; they paid $2.45M for a 7% stake in IBC, a joint venture set up to develop a cancer drug combining a bi-specific antibody from Immunomedics with a targeting technology from Beckman Coulter
ICAgen Inc. (Round ND)
Research Triangle Park, N.C.
11/30
19
ICAgen completed private placements to new and existing investors; lead investors were Alta Partners and Chase Capital Partners; existing investors included Venrock Associates, Gutrafin and Hoegh Invest AS; new investors included New Medical Technologies and Fugijin
Idun Pharmaceuticals (mezzanine)
La Jolla, Calif.
9/14
7.4
Idun completed a private placement of preferred stock; lead investor was John Hancock Mutual Life Insurance Co.; other participants were Venrock Associates, Accel Partners, Institutional Venture Partners, ARCH Venture Fund and Delphi Ventures
Immunicon Corp. (mezzanine)
Huntingdon Valley, Pa.
3/24
10.7
Immunicon completed convertible preferred equity offering totaling $10.7M in cash and conversion of bridge loans; lead investors were MDS Capital Corp. and TL Ventures; also participating were Canaan Partners, which was instrumental in structuring the financing and conducting additional diligence, and Anthem Capital
Inpharmatica Ltd. (2nd round)
London
3/9
4.8
3i plc and GIMV invested US$4.8M in Inpharmatica equity
Inspire Pharmaceuticals (Round ND)
Durham, N.C.
11/2
12.4
Inspire completed a private placement of preferred stock to new and existing investors; Pacific Growth Equities acted as placement agent; lead investors were New Medical Technologies and InterWest Partners
InterMune Pharmaceuticals Inc. (1st round)
Palo Alto, Calif.
4/30
6
Connetics Corp. launched spin-off company InterMune through sale of majority interest to outside investors; InterMune raised $6M through a self-managed private placement of Series A preferred stock with lead investor Sanderling, and with co-investors BioAsia Investments LLC and Charter Ventures III; when Connetics created the company, it retained a 10% equity position and received a $0.5M cash payment and will receive additional cash and equity payments over the next 3 years
InterMune Pharmaceuticals Inc. (1st round)
Palo Alto, Calif.
8/20
1.5
A spin-off company of Connectics Corp., InterMune completed an additional closing of its Series A preferred stock financing, the first closing of which was completed in April 1999; a new investor, Sofinnova Ventures, purchased $1M of Series A preferred stock and will close on an additional $0.5M
IntraBiotics Pharmaceuticals Inc.
Mountain View, Calif.
2/1
23
International Biomedicine Management Partners led this financing round; new investors included the Kaufmann Fund, Vulcan Northwest Ventures, New England Partners, OrbiMed Advisors and unidentified Danish investors; Den Danske Bank and Legg Mason Wood Walker Inc. acted as the placement agents
IntraBiotics Pharmaceuticals Inc. (Series H)
Mountain View, Calif.
11/17
25
IntraBiotics completed a private placement of Series H preferred shares; Investor AB, of Sweden, led the round; existing investors included Vulcan Northwest Ventures and New England Partners; participating investors also received warrants to purchase additional Series H preferred shares
IntraTherapeutics Inc. (mezzanine)
St. Paul, Minn.
10/8
7.5
IntraTherapeutics completed a private placement of convertible preferred stock; placement agent was MPM Asset Management; a follow-on investment was made by Brentwood Venture Capital
IsoTis BV (Round ND)
Bilthoven, the Netherlands
6/21
Euro18.2 (US$18.8)
Private placement was managed by ABN AMRO Corporate Finance and attracted funding from existing shareholders (Atlas Venture, 3i Group and GIMV) and new investors (Alpinvest Holding and ABN AMRO Participaties, Chase Capital Partners Europe and Trust Capital Technology)
Kimeragen Inc. (Round ND)
Newtown, Pa.
5/18
7.5
Burrill & Company, in association with other Kimeragen investors, closed a private placement of up to $15M; Kimeragen received $7.5M initially, and could receive an additional $7.5M upon meeting certain business development milestones
Kinetek Pharmaceuticals Inc. (1st round)
Vancouver, British Columbia
8/18
C$7.9 (US$5.3)
Kinetek raised C$7.9M (US$5.3M) in an equity financing made by a syndicate of six venture capital funds and private investors; the financing was led by Ventures West B.C. Technology Investment Fund, Bank of Montreal Capital Corp., Working Opportunity Fund and Royal Bank Capital Corp.; other investors included Exceptional Technologies (VCC) Funds, Trian Equities Ltd. and undisclosed private parties
Kinetix Pharmaceuticals Inc. (2nd round)
Medford, Mass.
4/15
8.8
Kinetix completed $8.8M Series B private financing; participants include new investor Shroder Ventures International Life Sciences Fund, along with existing investors JAFCO Co. Ltd., Lombard-Odier Immunology Fund, Zero Stage Capital, and The Novartis Venture Fund
KuDOS Pharmaceuticals Ltd. (1st round)
Cambridge, England
N/A
5 (US$8)
KuDOS raised #5M in first round of financing from Advent 3i plc and Schroder Ventures
Link Technology Inc. (seed)
Research Triangle Park, N.C.
9/23
0.75
Link Technology completed a $0.75M round of financing, including a $0.5M investment by Access Investment Partners, of Westport, Connecticut
Maxygen Inc. (4th round)
Redwood City, Calif.
7/14
20
Private placement by new and existing investors; existing investors included lead investor Technogen Associates LP; new investors included Lombard Odier, Invemed Fund LP, and CMEA Life Sciences Fund
Medinox Inc. (mezzanine)
San Diego
6/22
7.4
Investors included international group of venture capital funds and private investors in oversubscribed financing
Microscience Ltd. (Round ND)
London
6/8
9 (US$14.2)
Microscience completed a #9M financing round from investment funds advised by Apax Partners and Merlin Ventures; the Merlin Healthcare fund has an option to invest an additional #3M over the next year
Morphochem AG (2nd round)
Munich, Germany
9/1
DM28 US$15.1
Morphochem completed a private financing round that raised DM28M from European and U.S. investors; new equity funding of DM22M (US$11.9M) was raised from existing investors including Techno Venture Management, of Munich, Germany; Alta Berkeley Associates, of London; and Alta California Partners, of San Franscisco; the complete financing included silent partnership and leasing programs of DM6M (US$3.2M)
Myogen Inc. (Series C)
Boulder, Colo.
12/15
18
Myogen completed an $18M private placement led by New Enterprise Associates; existing investors included Sequel Venture Partners, Crosspoint Venture Partners and InterWest Partners; new investors were CMEA Ventures and New Venture Partners
Novirio Pharmaceuticals Ltd. (Round ND)
Cambridge, Mass.
11/5
12.5
Novirio completed a private placement of preferred stock, led by TVM Techno Venture Management; other investors included Nomura International plc, BB BioVentures and other funds managed by MPM, the company's initial investor and major shareholder
Orchid Biocomputer Inc.
Princeton, N.J.
3/10
16
Orchid established a lease financing line package with Oxford Venture Finance; Orchid will be immediately provided $6M toward an eventual lease financing package of $16M, contingent upon completion of additional stages
OriGenix Technologies Inc. (start-up funding)
Montreal
1/28
4
OriGenix was founded by Hybridon Inc. and 3 Canadian venture capital firms; Hybridon, which owns a 49% stake, has licensed certain antisense compounds and other technology to OriGenix; the venture capital firms (BioCapital Investments LP, Le Fonds de Solidarite des Travailleurs de Quebec and Societe Innovatech du Grand Montreal) will invest a total of US$3.95M; for an initial investment of US$2.63M, the firms get a 51% stake in OriGenix; the remaining US$1.32M investment will bring their ownership to 60% (prices converted at a rate of C$1.52/ US$1)
Origenix Technologies Inc. (Round ND)
Montreal
12/13
2
Origenix received gross proceeds of $2M from the closing of the final tranche of its previously announced $6M equity investment; the new investment was triggered by the achievement of certain specific milestones as stipulated in the original subscription agreement
Pangea Systems Inc. (2nd round)
Oakland, Calif.
2/22
4
The company raised an additional $4M in its Series C financing (it raised $15M on 12/14/98); the additional financing was led by The Burrill Agbio Capital Fund and Mitsui & Co. (USA) Inc.
Pentose Pharmaceuticals Inc. (2nd round)
Cambridge, Mass.
1/6
7
Participants in this financing round include new investor JAFCO Co. Ltd. and founding investor Ampersand Ventures
Pepgen Corp. (an affiliate of Calypte Biomedical Corp.) (Round ND)
Alameda, Calif.
10/6
3.8
Pepgen secured $3.8M in an undisclosed round of financing; lead investors were BioAsia Investments and Crown Advisors; further details ND
Pharmadigm Inc. (3rd round)
Salt Lake City
4/19
8.6
Pharmadigm completed a self-managed private placement of Series D convertible preferred stock, of which $6.5M was raised by Zurichbased venture capitalist Peter Friedli of Friedli Corporate Finance
Quorex Pharmaceuticals Inc. (Series A)
Carlsbad, Calif.
12/6
1.1
Quorex completed the first closing of a $1.1M equity financing; investors included TullisDickerson & Co. Inc.
Regen Biologics Inc.
Redwood City, Calif.
1/25
6
Regen raised $6M in financing, consisting of a $4M preferred equity investment and a $2M line of credit from Sulzermedica
Reprogenesis Inc. (2nd round)
Cambridge, Mass.
9/15
10.5
Reprogenesis completed a second private financing round; existing investors were Hambrecht & Quist Capital Management, Essex Woodlands Health Ventures and Piedmont Venture Partners; new investor was A.M. Pappas & Associates
RxKinetix Inc. (1st and 2nd rounds)
Louisville, Colo.
9/1
4.1
RxKinetix announced on Sept. 1 the completion of $4.1M in sales of newly issued shares of preferred stock year-to-date; the first private offering of $1.1M closed March 16, 1999; the second private offering of $3M closed August 23, 1999
Salus Therapeutics Inc. (Round ND)
Salt Lake City
11/17
1
Salus received a $1M investment from Utah Ventures II LP; further details ND
Sangamo BioSciences Inc. (3rd round)
Point Richmond, Calif.
10/18
7.5
Sangamo raised $7.5M in a private placement of preferred stock; existing investors included JAFCO Co. and Lombard Odier Zurich Ltd.; new investors included The Palladin Group LP and Stephens Inc.
Santarus Inc. (1st round)
San Diego
8/17
4.8
Santarus received $4.8M in seed capital from St. Paul Venture Capital, Windamere Venture Partners LLC, Mayo Medical Ventures and other private investors
Sequenom (3rd round)
San Diego
4/19
37
Sequenom completed a $37M equity financing round; new investors include Nomura International, Deutsche Bank, Haspa Bank, Euroventures, Vertex Capital, Alafi Capital and Value Management & Research; Index Securities acted as a placement agent for a portion of the financing; previous investors include Techno Venture Management, Alpinvest International, Global Life Sciences, Dresdner Kleinwort Benson and S.R. One Ltd
Structural GenomiX (Series A)
San Diego
12/15
7.5
Structural GenomiX completed a $7.5M round of initial venture capital financing; investors were Atlas Venture, Prospect Venture Partners and Appletree Partners
Sunesis Pharmaceuticals Inc. (Series B)
Redwood City, Calif.
12/6
25.2
Sunesis completed a Series B preferred stock financing led by new investors E.M. Warburg, Pincus & Co. LLC, International Biomedicines and New Medical Technologies; existing investors included Mayfield Fund, Venrock Associates, Abingworth Management and Skyline Ventures; Hamilton Capital Ltd. acted as placement agent for a portion of the financing
Symyx Technologies
Santa Clara, Calif.
1/12
23
The company raised $10M in equipment financing and $13M in private equity; the equity financing was raised primarily from existing investors with Aventis Research and Technology (a subsidiary of Hoechst AG) also participating. Lease Management Services Inc. and Transamerica Business Credit Corp. provided the equipment financing
t. Breeders Inc. (Round ND)
Worcester, Mass.
7/7
5.95
t. Breeders received an equity capital financing from a syndicate of four venture capital firms led by MPM Asset Management, of Cambridge, Mass., and including Javelin Capital, of Birmingham, Ala.; Seaflower Associates, of Waltham, Mass.; and Zero Stage Capital, also of Cambridge
Tanox Inc. (Round ND)
Houston
12/13
23.7
Tanox completed two private placements covering the sale of 1.18M shares of unregistered common stock to select institutional and accredited investors in Europe and Taiwan; KBC Securities NV acted as placement agent in Europe; further details ND
TerraGen Discovery Inc. (formerly TerraGen Diversity; 2nd round)
Vancouver, British Columbia
4/19
C$8 (US$5.5)
TerraGen raised C$8M (US $5.5M) in private financing to support acquisitions of ChromaXome Corp. and Xenova Discovery Ltd.; MDS Capital Corp., including MDS Ventures Pacific Inc. and Canadian Medical Discoveries Fund Inc., led the financing by existing investors, which included Biotechnology Investments Ltd., S.R. One Ltd. and the Business Development Bank of Canada
Therion Biologics Corp. (Round ND)
Cambridge, Mass.
6/28
10.5
New investors included lead investor Sofinov, Pacific Horizon Ventures, and BioVentures Investors; major existing shareholders also participated: SR One Ltd., H&Q Healthcare Investors, H&Q Life Science Investors, Loeb Investors, Venture Capital Fund of America, Northwood Ventures, New York Life Insurance Company, Singapore Bio-Innovations and Sidney R. Knafel
Third Wave Technologies Inc. (mezzanine)
Madison, Wis.
7/27
19.5
Third Wave raised $19.5M in a private round of equity financing; new investors included Shroder Ventures International Life Sciences Fund II, The Wellcome Trust, SR One, and MVM Ltd; existing investors in this round included Venture Investors and Kenneth R. McGuire
Triad Biotechnology Inc. (seed)
Rancho Santa Fe, Calif.
7/2
12
Triad completed a Series A preferred stock financing; investors included Skyline Ventures, GeneChem Technologies Venture Fund, Hambrecht & Quist Life Science Investors, H&Q Healthcare Investors and Lombard Odier
UroGenesys Inc. (2nd round)
Santa Monica, Calif.
10/11
11.3
UroGenesys raised $11.3M in a private placement of Series B preferred stock; investors included most of the company's Series A stockholders, as well as a number of new investors, including Lombard Odier & Cie
Variagenics Inc. (2nd round)
Cambridge, Mass.
8/2
19
Variagenics completed a $19M round of financing led by The Sprout Group, the venture capital affiliate of Donaldson, Lufkin & Jenrette; existing investors included Atlas Venture, Oxford Bioscience Partners, Forward Ventures, Kummell Investments Ltd., Goldman Sachs & Co. and Advent International; the financing included new investor A.M. Pappas and Associates
Vascular Genetics Inc. (1st round)
Durham, N.C.
3/29
ND
The investment is in the form of a private placement on behalf of a consortium of individuals, based on achievement of milestones by Vascular Genetics, at a final post-money valuation of $63.5M
Versicor Inc. (Round ND)
Fremont, Calif.
11/3
40
Versicor completed a round of private equity financing, led by Patricof & Co. Ventures Inc.; new investors included Apax Partners Europe, Apax Partners France and Schroeder Ventures; existing investors included HealthCare Ventures, New Enterprise Associates, Abingworth Ltd., Hambrecht & Quist Capital Management, Sepracor Inc., S.R. One Ltd. and Rho Management
Versicor Inc.
Fremont, Calif.
12/9
0.5
Versicor received a $0.5M milestone payment from Novartis Pharma AG under the terms of their collaboration for the discovery of antibacterials that inhibit deformylase and the Mur pathway
VitaGen Inc. (mezzanine)
La Jolla, Calif.
6/24
10.5
VitaGen received $10.5M from shareholders through a series of preferred stock offerings; lead shareholders include Chase Capital Partners, Becton Dickinson, New York Life and Radius Health Ventures; financing structured by VitaGen and the law firm Sheppard, Mullin, Richter & Hampton (6/24)
Xencor Inc. (2nd round)
Pasadena, Calif.
6/14
12.3
Stafford Investments LLC led financing
Zarix Ltd. (1st round)
Hamilton, Bermuda
1/25
5.5
Zarix, an Irish company, sold $5.45M in preferred stock to an international consortium of investors, led by Vernon International Ltd. and including previous investors BioAsia Investments LLC, New York Life Insurance and EJ Financial Enterprises Inc.rnational Ltd. and including previous investors BioAsia Invest- ments LLC, New York Life Insurance and EJ Financial Enterprises Inc.
See subscription options